Compare · AMGN vs RXRX
AMGN vs RXRX
Side-by-side comparison of Amgen Inc. (AMGN) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 125.5x RXRX ($1.91B).
- Over the past year, AMGN is up 52.8% and RXRX is down 26.3% - AMGN leads by 79.1 points.
- AMGN has been more active in the news (18 items in the past 4 weeks vs 9 for RXRX).
- AMGN has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Amgen Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $442.23-0.36%
- $3.56+9.71%
- Market cap
- $239.09B
- $1.91B
- 1M return
- +17.61%
- +18.27%
- 1Y return
- +52.83%
- -26.29%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2021
- News (4w)
- 18
- 9
- Recent ratings
- 25
- 10
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest RXRX
- CEO and President Khan Najat covered exercise/tax liability with 80,498 shares, decreasing direct ownership by 4% to 2,095,298 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,076,858 units (SEC Form 4) (for withholding tax)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,043,837 units (SEC Form 4) to cover taxes
- SEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.
- Director Borgeson Blake sold $97,500 worth of shares (30,000 units at $3.25) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,188,287 units (SEC Form 4)
- SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.
- Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules